• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

The Charts of Cytosorbents Suggest We Might See Further Gains Ahead

CTSO makes a unique blood purification therapy.
By BRUCE KAMICH
May 08, 2020 | 02:24 PM EDT
Stocks quotes in this article: CTSO

During the fast-paced 'Lightning Round' of Mad Money Thursday night, Jim Cramer answered a caller about Cytosorbents (CTSO) : "You're fine with this one." Let's check out the charts of this maker of a unique blood purification therapy to control deadly inflammation in life-threatening illnesses in the ICU and cardiac surgery.   

 
In this daily bar chart of CTSO, below, we can see a rounded bottom formation from August through March's correction and retest. Since the March retest prices have been soaring.
 
CTSO is above the rising 50-day moving average line and above the rising 200-day moving average line. A bullish golden cross can be seen in late March.
 
The daily On-Balance-Volume (OBV) line has been rising strongly to confirm the bullish price action. The Moving Average Convergence Divergence (MACD) oscillator is also bullish.   
 
 
In this weekly bar chart of CTSO, below, we can see that prices have rallied after a long decline. Prices are above the rising 40-week moving average line.
 
The weekly OBV line has turned up strongly and the MACD oscillator is bullish too.  
 
 
 
In this daily Point and Figure chart of CTSO, below, we can see that the chart is projecting the $13 area as a price target.  
 
 
In this weekly Point and Figure chart of CTSO, below, we can see a potential $16 price target. 
 
Bottom line strategy: The chart of CTSO is pointed up but I don't consider CTSO an attractive trade. Maybe it can rally to $13 but I think I would have to risk a close below $8. Not my kind of risk/reward ratio. 
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Trading | Health Care Equipment & Services | Healthcare | Mad Money

More from Investing

Carnival's Valuation Is a Head Scratcher

Jonathan Heller
Jan 15, 2021 1:33 PM EST

Markets may be painting an overly rosy picture for the cruise ship company.

Beyond Meat May Simmer Down After Its Latest Rally

Bruce Kamich
Jan 15, 2021 12:56 PM EST

Has Thursday's rally made a significant change to the charts?

I Find Draganfly's Connection to American Airlines Intriguing

Timothy Collins
Jan 15, 2021 12:29 PM EST

Drones are set to become a bigger and bigger part of the commercial world and our day-to-day lives.

GameStop's Charts Show Us More Risk Than Reward

Bruce Kamich
Jan 15, 2021 12:04 PM EST

Let's check and see what clues we can glean from the charts and indicators.

An Undervalued Stock Yielding Over 6%

Bob Ciura
Jan 15, 2021 12:00 PM EST

With a high yield of 6.4%, this is an attractive stock for income investors.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    When it's time to sell, will you act or freeze?
  • 08:35 AM EST GARY BERMAN

    Wednesday Morning Fibocall for 1/13/2021

    Lower highs... SPX (Long-Term View) The 1/8/2...
  • 08:07 AM EST GARY BERMAN

    Tuesday Morning Fibocall for 1/12/2021

    Watch if the recent trend of lower highs continues...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login